26 completed. 26 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 26 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 2 | Completed 2 |
Follow Language Disorders: new trials by email Literature Review of Language Disorders trials Research Report on Language Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Prior Learning on Word Learning VAULT Phase 4 - Language Development Disorders | Phase 2 | Completed | University of Arizona | 22 | 2023-06-01 | 2025-06-27 |
| Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia | Phase 2 | Completed | NYU Langone Health | 11 | 2022-12-24 | 2024-09-19 |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) Ecopipam, Placebo - Childhood-Onset Fluency Disorder (Stuttering) | Phase 2 | Completed | Emalex Biosciences Inc. | 68 | 2020-10-22 | 2026-09-23 |
| Speech Entrainment for Aphasia Recovery SET (Speech Entrainment Therapy) 3 weeks, SET (Speech Entrainment Therapy) 4.5 weeks, SET (Speech Entrainment Therapy) 6 weeks - Aphasia, Aphasia Non Fluent | Phase 2 | Completed | Medical University of South Carolina | 80 | 2020-08-21 | 2025-11-14 |
| Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS high-definition transcranial direct current stimulation, modified constraint-induced language therapy - Primary Progressive Aphasia | Phase 2 | Completed | University of Pennsylvania | 76 | 2020-08-17 | 2026-10-19 |
| Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). - Language Delay, Language; Developmental Disorder, Expressive | Phase 1 / Phase 2 | Completed | Russian Academy of Medical Sciences | 14 | 2020-02-01 | 2022-05-02 |
| Maximizing Outcomes for Preschoolers With Developmental Language Disorders the Enhanced Milieu Teaching-Sentence Focus - Developmental Language Disorder | Phase 2 | Completed | Northwestern University | 108 | 2019-04-04 | 2026-08-19 |
| Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia Active TMS, Sham TMS, CILT - Aphasia | Phase 2 | Completed | H. Branch Coslett | 86 | 2019-03-28 | 2025-10-14 |
| PCT for Speech, Language, and Cognitive Intervention in Stroke Patients PCT, Workbooks - Aphasia, Acquired | Phase 2 | Completed | The Learning Corp | 36 | 2019-03-18 | 2020-07-27 |
| Building Sentences With Preschoolers Who Use AAC AAC Generative Language Intervention, Standard of Care / Business as Usual - Down Syndrome, Speech and Language Disorder | Phase 2 | Completed | University of Central Florida | 70 | 2018-05-11 | 2024-01-08 |
| Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study HD-tDCS (Soterix Medical, Active), HD-tDCS (Soterix Medical, Sham) - Chronic Aphasia | Phase 2 | Completed | Soterix Medical | 58 | 2015-07-01 | 2023-12-05 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine Fluoxetine - Selective Mutism, Social Anxiety | Phase 2 | Completed | Michigan State University | 6 | 2014-01-01 | 2022-05-18 |
| Brain Stimulation and Aphasia Treatment Activa Dose II Real tDCS, Activa Dose II Sham tDCS - Aphasia | Phase 2 | Completed | University of South Carolina | 74 | 2012-04-01 | 2019-08-20 |
| Building Complex Language Complex sentence treatment protocol - Language Development Disorders, Learning Disorders | Phase 1 / Phase 2 | Completed | Governors State University | 31 | 2011-04-01 | 2013-11-25 |
| Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Verb Network Strengthening Treatment - Aphasia | Phase 2 | Completed | US Department of Veterans Affairs | 11 | 2011-03-01 | 2015-06-09 |
| Randomised Controlled Treatment Study of Selective Mutism Stimulus fading procedures, Guidance on defocused communication - Selective Mutism | Phase 2 | Completed | Regionsenter for barn og unges psykiske helse | 24 | 2009-06-01 | 2014-06-20 |
| My Scrivener® - Measuring Effectiveness and Dose Response in Children My Scrivener(R) - Asperger's Syndrome, Dyslexia | Phase 1 / Phase 2 | Completed | Obslap Research LLC | 176 | 2009-04-01 | 2010-10-28 |
| Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study MindFrame System - Ischemic Stroke | Phase 2 | Completed | MindFrame, Inc. | 40 | 2009-03-01 | 2012-07-26 |
Showing 20 of 26. Sign in to see all of them.
Aphasia (11) · Stroke (6) · Language (4) · Language Development Disorders (4) · Aphasia, Primary Progressive (3) · Attention Deficit Disorder with Hyperactivity (3) · Mutism (3) · Aphasia, Broca (2) · Central Nervous System Diseases (2) · Communication Disorders (2) · Dementia (2) · Dyslexia (2) · Ischemic Stroke (2) · Speech Disorders (2)
Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (26) · Nervous System Diseases (25) · Neurobehavioral Manifestations (25) · Neurologic Manifestations (25) · Communication Disorders (24) · Speech Disorders (16) · Mental Disorders (12) · Neurodevelopmental Disorders (10) · Brain Diseases (9) · Central Nervous System Diseases (8) · Behavior (6) · Cardiovascular Diseases (6) · Cerebrovascular Disorders (6)
Commerce (1) · Fluoxetine (1) · Methods (1) · SET protein, human (1) · Standard of Care (1) · Therapeutics (1) · Transcranial Direct Current Stimulation (1) · carbidopa, levodopa drug combination (1) · ecopipam (1) · pagoclone (1) · rotigotine (1)
Climb Up Kids (1) · Emalex Biosciences Inc. (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Governors State University (1) · H. Branch Coslett (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · Lamar University (1) · Medical University of South Carolina (1) · Michigan State University (1) · MindFrame, Inc. (1) · NYU Langone Health (1) · Northwestern University (1) · Obslap Research LLC (1) · Regionsenter for barn og unges psykiske helse (1) · Russian Academy of Medical Sciences (1)
United States (21) · Germany (1) · India (1) · Italy (1) · Norway (1) · Russia (1)
Abhishek Datta, Ph.D (1) · Alessandro Martorana, MD, PhD (1) · Alexander A Ostanin, MD, PhD (1) · Ann Kaiser, PhD (1) · Atul R Mahableshwarkar, MD, DFAPA (1) · Bruce Crosson, PhD (1) · Catherine H Balthazar, PhD (1) · Cheryl M Scott, PhD (1) · Devendra Mehta, MBBS MSC MRCP (1) · Elena R Chernykh, MD, PhD (1) · Gayatri Devi, MD (1) · Giacomo Koch, MD (1) · H. Branch Coslett, MD (1) · Hanne Kristensen, MD, PhD (1) · Jed Magen, DO (1)
PMID 23106988, PMID 25267381, PMID 29357099, PMID 30128538, PMID 32878377, PMID 33643204, PMID 40809903
R01DC007387 (1), R01DC015642 (1), R01DC016321 (1), R01DC016800 (1), R15DC009027 (1), R44NS092144 (1), U01DC011739 (1), U01DC017521 (1)